Mon, Apr 21, 2014, 5:59 AM EDT - U.S. Markets open in 3 hrs 31 mins

Recent

% | $
Quotes you view appear here for quick access.

Clovis Oncology, Inc. Message Board

smithjjj5 18 posts  |  Last Activity: Mar 25, 2014 4:11 PM Member since: Sep 18, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • smithjjj5 by smithjjj5 Mar 25, 2014 4:11 PM Flag

    Fourth Quarter 2013 Highlights
    -- Total revenues increased by 63.5% to RMB98.9 million (US$16.3 million)
    from RMB60.5 million in the prior year period.

    -- Revenues from mobile application products and services increased by
    230.7% to RMB50.9 million (US$8.4 million) from RMB15.4 million in the
    prior year period.

    -- Net income increased by 76.4% to RMB30.8 million (US$5.1 million) from
    RMB17.5 million in the prior year period.

    -- Adjusted earnings before interest and tax, or adjusted EBIT1 increased by
    228.9% to RMB34.9 million (US$5.8 million) from RMB10.6 million in the
    prior year period.
    Full Year 2013 Highlights
    -- Total revenues increased by 77.5% to RMB328.8 million (US$54.3 million)
    from RMB185.2 million in 2012.

    -- Revenues from mobile application products and services increased by
    350.3% to RMB153.4 million (US$25.3 million) from RMB34.1 million in
    2012.

    -- Net income increased by 505.3% to RMB91.8 million (US$15.2 million) from
    RMB15.2 million in 2012.

    -- Adjusted EBIT increased significantly to RMB107.7 million (US$17.8
    million) from RMB8.5 million in 2012.
    Key Operating Metrics
    -- As of December 31, 2013, total users of GO series products reached 364
    million representing a 76.0% year-over-year increase from 207 million as
    of December 31, 2012.

    -- Total average monthly active users (MAU) of GO series products increased
    by 44.6% to 94 million in the fourth quarter 2013 from 65 million in the
    prior year period.

  • smithjjj5 by smithjjj5 Mar 20, 2014 5:00 PM Flag

    This really pops out..
    Net income for the year ended December 31, 2013 was $6.8 million, or $0.24 per basic and diluted share, compared to a net loss of $20.4 million, or $1.03 per basic and diluted share, for the same period in 2012.

    Net loss for the three-month period ended December 31, 2013 was $8.2 million, or $0.22 per basic and diluted share, compared to $6.9 million, or $0.29 per basic and diluted share, for the same period in 2012.

  • smithjjj5 smithjjj5 Mar 15, 2014 8:31 AM Flag

    From the Dec.2, letter to shareholders...
    We expect that our cash position at the end of 2013 of more than $20 million along with the projected revenue from our testing services will be sufficient to fund our operations well into 2015.
    They have -0- debt.

  • Aug. 8th they reported and beat expectations. Share price was .40, it traded as high as .4199.
    Nov.14th they missed expectations, share price was .61 and traded as high as .67 on optimistic comments from Mr. Marsh. He stated "Plug Power is currently in negotiations with a number of key customers to deploy GenDrive at notable site distribution centers. In some of these deals, Plug Power will provide hydrogen refueling services and fuel infrastructure. We expect a portion of these agreements to close before the end of 2013." along with other info. I checked, I have not found any agreements that closed before the end of 2013. Now the share price is 7.00 approx. with a market cap of 697 million. I would think they need to blow their numbers away to support that price.

  • smithjjj5 by smithjjj5 Mar 11, 2014 6:05 PM Flag

    *BZ: BiotechBreakthroughs Tweet: $CDTI has had a relationship with Honda for over a decade. Buyers should exercise extreme caution (Benzinga)

  • smithjjj5 by smithjjj5 Mar 6, 2014 5:33 PM Flag

    For the full year 2013, OVA1 tests totaled 17,004 tests, up 3% from 16,460 in 2012.

    Fourth quarter of 2013 4,218 OVA1 tests performed
    and 16,745 OVA1 tests reported by Quest Diagnostics
    By comparison, in the fourth quarter of 2012, 4,260 OVA1 tests performed
    and 13,709 OVA1 tests reported by Quest Diagnostics as resolved in 2012.

    This does not strike me as impressive growth, the test was approved by the FDA Sept. 2009. Quest launched Ova1 March 2010 and pegged the market as 1 million women annually. In three years you would think they would has captured more of that market.

  • Citadel is beginning the process to provide a comprehensive real time fully electronic payment and banking solution that is safe, legal and fully compliant with Federal and State laws which would be an industry specific payment solution designed specifically for the legal marijuana industry. This will earmark the growing business plan of the companies banking solutions into one of the fastest growing industries.

  • smithjjj5 smithjjj5 Mar 5, 2014 5:50 PM Flag

    Still the full year is above expectations... seems that should counteract the next quarter downside guidance.

  • smithjjj5 smithjjj5 Mar 5, 2014 5:45 PM Flag

    Thanks just skimmed headlines, didn't see that.

  • smithjjj5 smithjjj5 Mar 5, 2014 5:00 PM Flag

    Maybe just not as strong as investors would like...

  • smithjjj5 smithjjj5 Mar 5, 2014 5:00 PM Flag

    Are you kidding me, where is the weak guidance?
    Wuxi Pharmatech (Cayman) Inc. (NYSE: WX) is looking for FY2014 EPS of $1.95-2.00 vs $1.89 analyst estimate. Sees sales of $660.0M-670.0M vs $667.40M estimate.

  • WEED 2: Cannabis Madness: Dr. Sanjay Gupta Reports"

    Premieres on CNN Tuesday, March 11 at 10 pm ET

    After sparking a national debate with his acclaimed documentary Weed, and op-ed "Why I changed my mind on weed," CNN's chief medical correspondent Dr. Sanjay Gupta delves deeper into the challenges of legalizing #$%$.

  • smithjjj5 by smithjjj5 Mar 5, 2014 1:43 PM Flag

    WEED 2: Cannabis Madness: Dr. Sanjay Gupta Reports"

    Premieres on CNN Tuesday, March 11 at 10 pm ET

    After sparking a national debate with his acclaimed documentary Weed, and op-ed "Why I changed my mind on weed," CNN's chief medical correspondent Dr. Sanjay Gupta delves deeper into the challenges of legalizing #$%$.

  • smithjjj5 by smithjjj5 Feb 26, 2014 4:15 PM Flag

    They beat...

    BioTelemetry 4Q EPS 0c BEAT (Dow Jones)
    4:05p
    BioTelemetry 4Q Net $23,000 BEAT (Dow Jones)
    4:05p
    BioTelemetry 4Q Rev $33.1M BEAT (Dow Jones)

  • smithjjj5 by smithjjj5 Jan 24, 2014 8:59 AM Flag

    GenVec Files $75M Mixed-Securities Shelf

  • smithjjj5 smithjjj5 Jan 21, 2014 2:51 PM Flag

    To me the most important paragraph in the release...
    E. Robert Wassman, MD, FAAP, FACMG, Rosetta Genomics' Chief Medical Officer, said, "It is becoming clear that the majority, if not all, CUP cases are not different, unique classes of cancer, but rather are poorly diagnosed examples of cancers that we already know respond to specific treatment regimens. The growing awareness of the importance of more accurately determining the tumor origin in hard-to-diagnose metastatic cancers and CUP and its utility in guiding optimal treatment decisions is reflected by increased physician use and expanding payer coverage of our Cancer Origin Test. We are pleased that Highmark recognizes the importance of diagnosing the tumor origin in patients with CUP, and that they have extended access to the Cancer Origin Test to physicians and eligible patients."

  • smithjjj5 smithjjj5 Jan 21, 2014 2:34 PM Flag

    The announcement of medicare coverage for its miRview mets2 sent it flying..

    "This is a major commercial achievement for Rosetta Genomics as Medicare coverage is a critical step toward widespread commercial adoption and payment for our lead diagnostic assay, miRview® mets², and enables access to this clinically valuable test to Medicare patients. This decision is important not only because Medicare is the largest U.S. payor, covering a large percentage of the patients for whom miRview® mets² has been ordered historically and would be expected to be ordered in the future, but also because private payors often look to Medicare's decisions when setting their own reimbursement policies," noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "We are particularly pleased with how rapidly we obtained Medicare coverage, as we launched our direct selling effort in the U.S. just one year ago.

    "The decision by Novitas to cover the miRview® mets² assay reflects the clinical importance of determining the tumor origin in hard-to-diagnose metastatic cancers and CUP. This is particularly important as new, targeted cancer treatments are developed for site-specific cancers. We believe that the miRview® mets² assay is an important tool that can improve the ability of physicians to accurately diagnose CUP in order to optimize treatment plans," added Mr. Berlin.

  • smithjjj5 smithjjj5 Jan 21, 2014 2:26 PM Flag

    I remember!

CLVS
54.85-1.37(-2.44%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
AstraZeneca PLC
NYSEThu, Apr 17, 2014 4:00 PM EDT
KeyCorp.
NYSEThu, Apr 17, 2014 4:01 PM EDT